The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Suven Life Sciences Secures Product Patents in India and USA

11-Dec-2017 | Source : AG-IP News | Visits : 4918
HYDERABAD - Suven Life Sciences Ltd announced in a press release that the grant of one (1) product patent from India (289123) and one (1) product patent from USA (9790211) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2033 respectively.

The granted claims of the patents include the class of selective Alpha4 Beta2 and 5-HT4 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.
 
share



Related Articles